BIO-TECHNE CORP shareholders Q2 2023

BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 514 filers reported holding BIO-TECHNE CORP in Q2 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.

BIO-TECHNE CORP shareholders Q2 2023
NameSharesValueWeighting ↓
Legacy Wealth Asset Management, LLC 8,936$729,4460.26%
THRIVENT FINANCIAL FOR LUTHERANS 1,305,973$106,6060.24%
Paradigm, Strategies in Wealth Management, LLC 4,373$356,9680.24%
BEACON INVESTMENT ADVISORY SERVICES, INC. 60,252$4,918,3710.23%
SNYDER CAPITAL MANAGEMENT L P 127,212$10,384,3160.22%
MARSHALL WACE, LLP 1,371,003$111,914,9750.22%
RMB Capital Management, LLC 79,349$6,477,2590.21%
First Light Asset Management, LLC 33,178$2,708,2870.21%
Inspire Investing, LLC 21,363$1,743,8620.21%
WILKINS INVESTMENT COUNSEL INC 9,325$7610.20%
MACQUARIE GROUP LTD 2,120,352$173,084,7850.20%
Hills Bank & Trust Co 18,619$1,519,8690.20%
Point72 Asset Management, L.P. 788,697$64,381,3360.19%
Sweet Financial Partners, LLC 8,880$724,8740.19%
Headlands Technologies LLC 7,107$580,1440.19%
Cherry Creek Investment Advisors, Inc. 3,146$256,8220.17%
S&CO INC 26,380$2,1530.17%
OMERS ADMINISTRATION Corp 135,807$11,085,9250.17%
Handelsbanken Fonder AB 383,848$31,3340.17%
Allspring Global Investments Holdings, LLC 1,278,098$104,331,3000.17%
About BIO-TECHNE CORP

Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.

Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.

In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.

Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.

Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BIO-TECHNE CORP's shareholders in Q2 2023. To view BIO-TECHNE CORP's shareholder history, click here.